Viking Therapeutics Inc (VKTX)

[BrazenBull]

I liked this paragraph.


Based on these numbers, and using an 18% discount rate, we arrive at a valuation of $8/share. We continue to believe that Viking’s shares are significantly undervalued. This is particularly evident on a comparative basis with Madrigal Pharmaceuticals, Inc. (MDGL), which is developing a TRß agonist that is also in Phase 2 testing for the treatment of fatty liver disease. We believe Viking’s TRß agonists have potentially superior efficacy and fail to see why Viking is trading at approximately 1/6th the valuation of Madrigal. Small-cap biotech investors should take a serious look at Viking ahead of data readouts later in 2017